Efficacy of fluoro-2-deoxy-d-glucose positron emission tomography to evaluate responses to concurrent chemoradiotherapy for head and neck squamous cell carcinoma

Auris Nasus Larynx

Volumn 38, Issue 6, 2011, Pages 724-729

  Mori, Makiko ^a   Tsukuda, Mamoru ^a   Horiuchi, Choichi ^a   Matsuda, Hideki ^a   Taguchi, Takahide ^a   Takahashi, Masahiro ^a   Nishimura, Goshi ^a   Komatsu, Masanori ^a   Niho, Tatsuo ^a   Sakuma, Naoko ^a   Shibata, Kunihiko ^a   Sugisaki, Satoko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Concurrent chemoradiotherapy; FDG PET; Head and neck cancer; Squamous cell carcinoma; SUVmax

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINATE CALCIUM; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; METHOTREXATE; UFT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CERVICAL LYMPH NODE; DIAGNOSTIC ACCURACY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; MOUTH CARCINOMA; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PARANASAL SINUS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; RADIOLOGICAL PARAMETERS; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 79959963905     PISSN: 03858146     EISSN: 18791476     Source Type: Journal    
DOI: 10.1016/j.anl.2011.04.013     Document Type: Article

References (28)

1. 18F] Fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol 2010, 28:1190-1195.
2. Porceddu S.V., Jarmolowski E., Hicks R.J., Ware R., Weih L., Rischin D., et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. Head Neck 2005, 27:175-1817.
3. Gourin C.G., Williams H.T., Seabolt W.N., Herdman A.V., Howington J.W., Terris D.J. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope 2006, 116:705-710.
4. Greven K.M., Williams D.W., Keyes J.W., McGuirt W.F., Watson N.E., Randall M.E., et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994, 74:1355-1359.
5. Allal A.S., Dulguerov P., Allaoua M., Haenggeli C.A., El-Ghazi el A., Lehmann W., et al. Standardized uptake value of 2-[(18)F] Fluoro-2-deoxy-d-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002, 20:1398-1404.
6. Minn H., Lapela M., Klemi P.J., Grénman R., Leskinen S., Lindholm P., et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997, 38:1907-1911.
7. Halfpenny W., Hain S.F., Biassoni L., Maisey M.N., Sherman J.A., McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002, 86:512-516.
8. Fleming A.J., Smith S.P., Paul C.M., Hall N.C., Daly B.T., Agrawal A., et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007, 117:1173-1179.
9. Horiuchi C., Taguchi T., Yoshida T., Nishimura G., Matsuda H., Tsukuda M., et al. Early assessment of clinical response to concurrent chemoradiotherapy in head and neck carcinoma using fluoro-2-deoxy-d-glucose positron emission tomography. Auris Nasus Larynx 2008, 35:103-108.
10. Taguchi T., Mikami Y., Kawai S., Arai Y., Mochimatsu I., Tsukuda M., et al. Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma. Anticancer Res 2003, 23:713-717.
11. Tsukuda M., Ishitoya J., Mikami Y., Matsuda H., Horiuchi C., Taguchi T., et al. Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 2009, 64:945-952.
12. Katori H., Tsukuda M., Mochimatu I., Ishitoya J., Kawai S., Mikami Y., et al. Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 2004, 90:348-352.
13. Taguchi T., Tsukuda M., Mikami Y., Matsuda H., Horiuchi C., Yoshida T., et al. Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovolin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx. Acta Otolaryngol 2006, 126:408-413.
14. Katori H., Tsukuda M., Taguchi T. Analysis of efficacy and toxicity of chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Caner Chemother Pharmacol 2007, 59:789-794.
15. Lee S.W., Nam S.Y., Im K.C., Kim J.S., Choi E.K., Ahn S.D., et al. Prediction of prognosis using standardized uptake value of 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008, 87:211-216.
16. Wong W.L., Chevretton E.B., McGurk M., Hussain K., Davis J., Beaney R., et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 1997, 22:209-214.
17. Laubenbacher C., Saumweber D., Wagner-Manslau C., Kau R.J., Herz M., Avril N., et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995, 36:1747-1757.
18. Zimmer L.A., Branstetter B.F., Nayak J.V., Johnson J.T. Current use of 18F-fluorodeoxyglucose-positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope 2005, 115:2029-2034.
19. Schwartz D.L., Rajendran J., Yueh B., Coltrera M.D., Leblanc M., Eary J., et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004, 130:1361-1367.
20. Kim S.Y., Lee S.W., Nam S.Y., Im K.C., Kim J.S., Oh S.J., et al. The feasibility of 18F-FDG PET scans 1 month after completing radiotherapy of squamous cell carcinoma of the head and neck. J Nucl Med 2007, 48:373-378.
21. Greven K.M., Williams D.W., McGuirt W.F., Harkness B.A., D'Agostino R.B., Watson N.E., et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001, 23:942-946.
22. Goerres G.W., Schmid D.T., Bandhauer F., Huguenin P.V., von Schulthess G.K., Schmid S., et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004, 130:105-109.
23. Hoshikawa H., Mitani T., Nishiyama Y., Yamamoto Y., Ohkawa M., Mori N. Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. Auris Nasus Larynx 2009, 36:192-198.
24. Rogers J.W., Greven K.M., McGuirt W.F., Keyes J.W., Williams D.W., Watson N.E., et al. Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy?. Int J Radiat Oncol Biol Phys 2004, 58:694-697.
25. Abgral R., Querellou S., Potard G., Le Roux P.Y., Le Duc-Pennec A., Marianovski R., et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up?. J Nucl Med 2009, 50:24-29.
26. Strobel K., Haerle S.K., Stoeckli S.J., Schrank M., Soyka J.D., Veit-Haibach P., et al. Head and neck squamous cell carcinoma (HNSCC)-detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging 2009, 36:919-927.
27. Gupta T., Jain S., Agarwal J.P., Rangarajan V., Purandare N., Ghosh-Laskar S., et al. Diagnostic performance of response assessment FDG-PET/CT in patients with head and neck squamous cell carcinoma treated with high-precision definitive (chemo)radiation. Radiother Oncol 2010, 97:194-199.
28. Haerle S.K., Huber G.F., Hany T.F., Ahmad N., Schmid D.T. Is there a correlation between 18F-FDG-PET standardized uptake value, T-classification, histological grading and the anatomic subsites in newly diagnosed squamous cell carcinoma of the head and neck?. Eur Arch Otorhinolaryngol 2010, 267:1635-1640.